A pragmatic approach is therefore warranted: replete deficiency with nutritional vitamin D (prefer D3; consider calcifediol when faster repletion or persistent SHPT is relevant), avoid mega-bolus dosing, and reserve active VDRAs for clear SHPT indications with careful calcium–phosphate–PTH monitoring—not as disease-modifying therapy in unselected CKD. The gene discussed is PTH; the disease is chronic kidney disease.